FDA Grants Genentech’s Perjeta Regimen Priority Review

07:57 EDT 2 Jul 2013 | PharmPro

Genentech, a member of the Roche Group, today announced that the FDA has accepted the company’s supplemental Biologics License Application (sBLA) for the use of a Perjeta® (pertuzumab) regimen before surgery (neoadjuvant treatment) in people with ...

Original Article: FDA Grants Genentech’s Perjeta Regimen Priority Review

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Genentech’s Perjeta Regimen Priority Review"

Search BioPortfolio:
Loading
Advertisement

Relevant Topic

The Top 100 Pharmaceutical Companies
Latest News Clinical Trials Research Drugs Reports Corporate
Top 100 Pharmaceutical Companies 2012 (SCRIP 100 - http://www.scrip100.com/scrip100.html) Rank (2011 in Brackets) Company SEARCH FOR COMPANY IN BIOPORTFOLIO'S BIOCORPORATE DATABASE 2012 pharma sales...

Advertisement

Searches Linking to this Story